Pfizer Discontinues Twice-Daily Obesity Pill After Study Showed High Side Effect Rates

Published on December 1, 2023

Pfizer on Friday said it would not advance the twice-daily version of its experimental weight-loss pill into further testing after a mid-stage clinical study showed high rates of obesity patients having trouble tolerating the drug. Pfizer’s drug, called danuglipron, is a GLP-1 receptor agonist that works the same way as weight-loss injections from Novo Nordisk and Eli Lilly, mimicking a hormone that controls feelings of satiety and how fast the contents of the stomach reach the gut. Unlike those drugs, danuglipron comes as an oral tablet, an advantage in convenience that Pfizer hoped could give it a competitive edge in a race to carve up the multibillion-dollar market....

Continue reading on website
Other news

Melatonin Use and Poisoning Reports Surging in Children, Revealing Concerning Problem

December 1, 2023
Insomnia and melatonin supplementation are not words one would often associate with children.But recent survey findings published in the Journal of the American Medical Association (JAMA) Pediatrics suggest that melatonin consumption in U.S. children and adolescents is “exceedingly common.”Around one-fifth of American children use melatonin for sleep, with some parents beginning administration to

Texas AG Ken Paxton Appeals Judge’s Ruling to Allow Feds to Continue Cutting Razor Wire at Southern Border

December 1, 2023
Texas Attorney General Ken Paxton has appealed a judge’s decision to continue allowing Border Patrol agents to cut concertina wire intended to stop illegal immigrants from crossing the southern border.“I am disappointed that the federal government’s blatant and disturbing efforts to subvert law and order at our State’s border with Mexico will be allowed to continue,” said Attorney General Paxton i